Immunovant (IMVT) CLO sells 5,165 shares to cover RSU tax bill

Rhea-AI Filing Summary

Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl reported an open-market sale of 5,165 shares of common stock on April 8, 2026 at a weighted average price of $24.83 per share. According to the disclosure, this sale was required to cover tax withholding obligations tied to the vesting and settlement of previously granted restricted stock units and was not a discretionary trade. Following the transaction, Van Tuyl directly holds 183,231 shares of Immunovant common stock.

Insider Trade Summary

Net Seller: 5,165 shares ($128,247)

Net Sell 1 txn

Insider Van Tuyl Christopher

Role Chief Legal Officer

Sold 5,165 shs ($128K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,165	$24.83	$128K

Holdings After Transaction: Common Stock — 183,231 shares (Direct)

Footnotes (1)

1. On April 1, 2025, the holder was granted 50,787 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 12,696 of these RSUs vested on April 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.54 - $25.39 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Key Figures

Shares sold: 5,165 shares Average sale price: $24.83 per share Post-transaction holdings: 183,231 shares +3 more

6 metrics

Shares sold 5,165 shares Open-market sale on April 8, 2026

Average sale price $24.83 per share Weighted average price for 5,165 shares

Post-transaction holdings 183,231 shares Common stock held directly after sale

RSUs granted 50,787 RSUs Grant on April 1, 2025

RSUs vested 12,696 RSUs Vested on April 1, 2026

Sale price range $24.54–$25.39 per share Multiple transactions within this range

Key Terms

restricted stock units, sell to cover, tax withholding obligations, weighted average price

4 terms

restricted stock units financial

"the holder was granted 50,787 restricted stock units ("RSUs")"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

tax withholding obligations financial

"shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting"

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Van Tuyl Christopher

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/08/2026		S		5,165(1)	D	$24.83(2)	183,231	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On April 1, 2025, the holder was granted 50,787 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 12,696 of these RSUs vested on April 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.54 - $25.39 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Remarks:

	/s/ Tiago Girao, attorney-in-fact for Christopher Van Tuyl	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Immunovant (IMVT) disclose about Christopher Van Tuyl’s latest stock sale?

Immunovant reported that Chief Legal Officer Christopher Van Tuyl sold 5,165 common shares at a weighted average price of $24.83 on April 8, 2026. The filing states this sale was solely to cover tax withholding obligations on vested restricted stock units.

Why did Immunovant’s CLO sell 5,165 IMVT shares?

The sale was made to cover tax withholding obligations arising from the vesting and settlement of previously granted restricted stock units. The company elected a mandatory "sell to cover" method, so the transaction did not represent a discretionary market decision by the executive.

How many Immunovant (IMVT) shares does Christopher Van Tuyl hold after this transaction?

After selling 5,165 shares to cover taxes, Christopher Van Tuyl directly holds 183,231 shares of Immunovant common stock. This figure, disclosed in the Form 4, shows his remaining equity position following the tax-related sale tied to RSU vesting.

What RSU grant and vesting events are linked to this Immunovant Form 4?

The filing notes that Van Tuyl was granted 50,787 restricted stock units on April 1, 2025. Of these, 12,696 RSUs vested on April 1, 2026. The April 8, 2026 share sale relates directly to tax withholding from this RSU vesting and settlement.

At what prices were the 5,165 Immunovant (IMVT) shares sold by the CLO?

The reported sale price is a weighted average of $24.83 per share. The shares were sold in multiple transactions at prices ranging from $24.54 to $25.39 per share, as detailed in the footnotes to the Form 4 filing.